GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Additional Paid-In Capital

KMDA (Kamada) Additional Paid-In Capital : $266.6 Mil(As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Kamada Additional Paid-In Capital?


Kamada's quarterly additional paid-in capital increased from Mar. 2024 ($266.2 Mil) to Jun. 2024 ($266.3 Mil) and increased from Jun. 2024 ($266.3 Mil) to Sep. 2024 ($266.6 Mil).

Kamada's annual additional paid-in capital increased from Dec. 2021 ($210.2 Mil) to Dec. 2022 ($210.5 Mil) and increased from Dec. 2022 ($210.5 Mil) to Dec. 2023 ($265.8 Mil).

Kamada Additional Paid-In Capital Historical Data

The historical data trend for Kamada's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Additional Paid-In Capital Chart

Kamada Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 180.82 209.76 210.20 210.50 265.85

Kamada Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 265.70 265.85 266.18 266.31 266.59

Kamada Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Kamada Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kamada's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Additional Paid-In Capital
Comparable Companies
XTAE:REKA XTAE:TKUN XTAE:CNTC XTAE:PNAX XTAE:NXTG XTAE:PMCN-M ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX
Traded in Other Exchanges
KMDA:Israel
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Website
https://www.kamada.com
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.